micafungin + liposomal amphotericin b

Micafungin + liposomal amphotericin B is a combination of two antifungal agents used experimentally and in salvage clinical settings for severe, invasive fungal infections (notably aspergillosis and mucormycosis). - **Micafungin** is an echinocandin antifungal that inhibits synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls, leading to cell wall instability and fungal death. - **Liposomal amphotericin B** is a polyene antifungal encapsulated in liposomes to reduce toxicity. It binds to ergosterol in fungal cell membranes, creating pores and resulting in cell death. - The combination has been assessed mainly in animal models and case reports, with the intent to provide broader or more potent antifungal activity and potentially prevent resistance or treatment failure. Evidence for additive or synergistic effects is mixed, and no large clinical trials have been completed[1][2][3]. - Main indications under investigation are invasive aspergillosis, mucormycosis, and other life-threatening fungal infections refractory to monotherapy, especially in immunocompromised patients[1][2][3].